171 related articles for article (PubMed ID: 18372137)
1. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy.
van der Molen AJ; Bellin MF
Eur J Radiol; 2008 May; 66(2):168-74. PubMed ID: 18372137
[TBL] [Abstract][Full Text] [Related]
2. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
3. MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):153-9. PubMed ID: 18343071
[TBL] [Abstract][Full Text] [Related]
4. [Does the administration of a high dose of a paramagnetic contrast medium (Gadovist) improve the diagnostic value of magnetic resonance tomography in glioblastomas?].
Hartmann M; Forsting M; Jansen O; Albert FK; Balzer T; Sartor K
Rofo; 1996 Feb; 164(2):119-25. PubMed ID: 8679973
[TBL] [Abstract][Full Text] [Related]
5. Extracellular gadolinium-based contrast media: an overview.
Bellin MF; Van Der Molen AJ
Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
[TBL] [Abstract][Full Text] [Related]
6. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
Bauner KU; Reiser MF; Huber AM
Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
[TBL] [Abstract][Full Text] [Related]
7. Investigation of sandwiched gadolinium (III) complexes with tungstosilicates as potential MRI contrast agents.
Sun G; Feng J; Wu H; Pei F; Fang K; Lei H
Magn Reson Imaging; 2004 Apr; 22(3):421-6. PubMed ID: 15062939
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Gd-CA: differences in prevalence of NSF.
Thomsen HS; Marckmann P
Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
[TBL] [Abstract][Full Text] [Related]
9. Contrast-dose relation in first-pass myocardial MR perfusion imaging.
Utz W; Niendorf T; Wassmuth R; Messroghli D; Dietz R; Schulz-Menger J
J Magn Reson Imaging; 2007 Jun; 25(6):1131-5. PubMed ID: 17520736
[TBL] [Abstract][Full Text] [Related]
10. Contrast agents: magnetic resonance.
Burtea C; Laurent S; Vander Elst L; Muller RN
Handb Exp Pharmacol; 2008; (185 Pt 1):135-65. PubMed ID: 18626802
[TBL] [Abstract][Full Text] [Related]
11. Chemistry of paramagnetic and diamagnetic contrast agents for Magnetic Resonance Imaging and Spectroscopy pH responsive contrast agents.
Pérez-Mayoral E; Negri V; Soler-Padrós J; Cerdán S; Ballesteros P
Eur J Radiol; 2008 Sep; 67(3):453-8. PubMed ID: 18455343
[TBL] [Abstract][Full Text] [Related]
12. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications.
Aime S; Castelli DD; Crich SG; Gianolio E; Terreno E
Acc Chem Res; 2009 Jul; 42(7):822-31. PubMed ID: 19534516
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging of active sacroiliitis: do we really need gadolinium?
Althoff CE; Feist E; Burova E; Eshed I; Bollow M; Hamm B; Hermann KG
Eur J Radiol; 2009 Aug; 71(2):232-6. PubMed ID: 19446974
[TBL] [Abstract][Full Text] [Related]
14. A novel cholic acid-based contrast enhancement agent for targeted MRI.
Chong HS; Song HA; Lim S; Macrenaris K; Ma X; Lee H; Bui P; Meade T
Bioorg Med Chem Lett; 2008 Apr; 18(7):2505-8. PubMed ID: 18337094
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
16. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents.
Wintersperger BJ; Runge VM; Tweedle MF; Jackson CB; Reiser MF
Invest Radiol; 2009 Feb; 44(2):89-94. PubMed ID: 19077910
[TBL] [Abstract][Full Text] [Related]
17. MR imaging of CNS tumors: are all contrast agents created the same?
Essig M
Neuroradiology; 2006 Apr; 48 Suppl 1():3-8. PubMed ID: 16699847
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium contrast agent selection and optimal use for body MR imaging.
Guglielmo FF; Mitchell DG; Gupta S
Radiol Clin North Am; 2014 Jul; 52(4):637-56. PubMed ID: 24889165
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-based magnetic resonance contrast agents for neuroradiology: an overview.
Kanal E
Magn Reson Imaging Clin N Am; 2012 Nov; 20(4):625-31. PubMed ID: 23088942
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.
Mohs AM; Lu ZR
Expert Opin Drug Deliv; 2007 Mar; 4(2):149-64. PubMed ID: 17335412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
